The genomic landscape of response to EGFR blockade in colorectal cancer
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted therapies are the monoclonal antibodies cetuximab and panitumumab, which prevent epidermal growth factor receptor (EGFR) activation. Recent studies have identified alterations in KRAS and other genes as likely mechanisms of primary and secondary resistance to anti-EGFR antibody therapy. Despite these efforts, additional mechanisms of resistance to EGFR blockade are thought to be present in colorectal cancer and little is known about determinants of sensitivity to this therapy. To examine the effect of somatic genetic changes in colorectal cancer on response to anti-EGFR antibody therapy, here we perform complete exome sequence and copy number analyses of 129 patient-derived tumour grafts and targeted genomic analyses of 55 patient tumours, all of which were KRAS wild-type. We analysed the response of tumours to anti-EGFR antibody blockade in tumour graft models and in clinical settings and functionally linked therapeutic responses to mutational data. In addition to previously identified genes, we detected mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 as potential mechanisms of primary resistance to this therapy. Novel alterations in the ectodomain of EGFR were identified in patients with acquired resistance to EGFR blockade. Amplifications and sequence changes in the tyrosine kinase receptor adaptor gene IRS2 were identified in tumours with increased sensitivity to anti-EGFR therapy. Therapeutic resistance to EGFR blockade could be overcome in tumour graft models through combinatorial therapies targeting actionable genes. These analyses provide a systematic approach to evaluating response to targeted therapies in human cancer, highlight new mechanisms of responsiveness to anti-EGFR therapies, and delineate new avenues for intervention in managing colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“EGFR somatic sequence changes, including G465R, G465E, S468R and S492R, located at the extracellular domains (ECDs) of the EGFR-mAb interaction interface, confer resistance to cetuximab and panitumumab by preventing mAb binding [10, 67, 68].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in late-line therapy, only 12–17% of patients have durable responses to anti-EGFR monotherapy [4]”
From Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Gene mutations downstream of the EGFR signalling pathway, including RAS/RAF/MEK and PI3K/AKT/mTOR, significantly contribute to drug resistance [9–11].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This is supported by our observation, consolidated after monitoring hundreds of mCRC PDXs exposed to cetuximab (10, 25, 27, 29, 30), that complete responses are exceptional events.”
From Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer (2023) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“A growing number of studies suggest that mutations in the extracellular domain (ECD) of the EGFR, such as S492R, G465E, R451C and K467T, prevent binding cetuximab and make CRC resistant to anti-EGFR mAbs [141,142,143,144].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [144]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Needleman, S. B., & Wunsch, C. D. (1970) · Journal of Molecular Biology · doi:10.1016/0022-2836(70)90057-4 · Cited by 11,288 · cited 1×
“Sequence reads were aligned against the human reference genome (version hg18) using ELAND with additional realignment of select regions using the Needleman-Wunsch method 35 .”
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“A mutation in the tumour was identified as a candidate somatic mutation only when (1) distinct paired reads contained the mutation in the tumour, (2) the number of distinct paired reads containing a particular mutation in the tumour was at least 2% of the total distinct read pairs for targeted analyses and 10% of read…”
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Self-citationPDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 6×
“Common CRC driver genes were identified at expected frequencies in the tumours analysed (Supplementary Tables 3–5).”
InfluentialSelf-citationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Coiffier, B., Osmanov, E. A., Hong, X., Scheliga, A. A. D. S., Mayer, J., Offner, F., Rule, S. A., Teixeira, A., Walewski, J. A., Vos, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045 · Cited by 1,631
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Cited by
Items 301–400 of 478
Liang, L., Liu, M., Sun, X., Yuan, Y., Peng, K., Rashid, K., Yu, Y., Cui, Y., Chen, Y., & Liu, T. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01829-8 · Cited by 12
Zhou, Y., Long, Y., Chen, Y., Liu, J., Pu, D., Huang, J., Bi, F., Li, Q., Gou, H., & Qiu, M. (2021) · Cancer Medicine · doi:10.1002/cam4.3876 · Cited by 11
Self-citationGrowth-inhibitory effects of TGFαL3-SEB chimeric protein on colon cancer cell line
Maleki, F., Sadeghifard, N., Hosseini, H. M., Bakhtiyari, S., Goleij, Z., Behzadi, E., Sedighian, H., & Fooladi, A. A. I. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.025 · Cited by 13
Hintzen, G., Dulat, H. J., & Rajkovic, E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.892212 · Cited by 9
“carry BRAF V600E (159), MAP2K1 (74) or PIK3CA (160) mutations, KRAS (161), ERBB2, MET or FGFR1 amplification”
BackgroundInfluentialCONNECTOR, fitting and clustering of longitudinal data to reveal a new risk stratification system
Pernice, S., Sirovich, R., Grassi, E., Viviani, M., Ferri, M., Sassi, F. P., Alessandrì, L., Tortarolo, D., Calogero, R., Trusolino, L., et al. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad201 · Cited by 11
“400 mCRC PDXs, part of which had been used in previous studies (Bertotti et al. 2011, 2015; Zanella et al. 2015; Isella et al. 2017; Lupo et al. 2020).”
InfluentialSelf-citationTsai, H., Lin, C., Sung, Y.-C., Chen, S., Chen, L., Jiang, J., & Wang, J. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02366-z · Cited by 10
“The mechanisms of resistance to anti-EGFR agents include gene mutations downstream of the EGFR signalling pathway, such as mutations of RAS/RAF/MEK and PIK3/AKT/mTOR, which contribute significantly to drug resistance [14, 15].”
BackgroundRachiglio, A. M., Sacco, A., Forgione, L., Esposito, C., Chicchinelli, N., & Normanno, N. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00004 · Cited by 10
“Mutations of the MAP2K1 gene coding for MEK1 have been consistently found to be associated with de novo and acquired resistance to anti-EGFR agents in different studies [118-121].”
BackgroundGarrido‐Laguna, I., Patel, S. B., & Gill, D. M. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s68558 · Cited by 9
“4) genes involved in alternative signaling pathways (MET, FGFR1).(77) In randomized trials with panitumumab in the”
Dankner, M., Rousselle, E., Petrecca, S., Fabi, F., Nowakowski, A., Lazaratos, A.-M., Rajadurai, C. V., Stein, A. J. B., Bian, D., Tai, P., et al. (2025) · JCO Precision Oncology · doi:10.1200/po.24.00199 · Cited by 13
“…role as de novo driver mutations, MAP2K1 mutations have also been demonstrated to emerge in the context of resistance to EGFR, BRAF, and MEK MAPK TT. 10,21,39-42 This suggests that the frequency of these mutations in the treatment-refractory setting may be higher than in treatment-na¨ ı ve tumors.”
Carosi, F., Filippini, D. M., Fabbri, L., Carlini, A., Monte, A., Sgarzi, M., Fermi, M., Querzoli, G., Romaniello, D., Mercante, G., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105207 · Cited by 9
Pérez‐Martínez, D., Infante, Y. C., Ramírez, B. S., & Rojas, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-16411-z · Cited by 8
Li, Z., Zhou, J., Gu, L., & Zhang, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-22768-y · Cited by 10
Kim, J. E., Kim, K. K., Kim, S. Y., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., & Kim, S. T. (2017) · Journal of Cancer · doi:10.7150/jca.19582 · Cited by 9
“The MAP2K1 K57T mutation is known to be a potential mechanism of primary and secondary resistance to EGFR inhibitors in metastatic CRC [26, 27] and has also been reported to promote resistance to BRAF and MEK inhibitors [25].”
BackgroundCrosstalk between TF/FVIIa and EGFR signaling in colorectal cancer cells
Chen, H., Wang, X., Wan, Y., & Tang, J. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1529123 · Cited by 8
“panitumumab are the most commonly used drugs for colorectal cancer.(1) Survival of advanced colorectal cancer patients”
BackgroundClinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.
Sandhu, J. S., Wang, C., & Fakih, M. (2020) · PubMed · doi:10.6004/jnccn.2019.7371 · Cited by 12
Liu, Y., Li, W., Lü, Z., Lu, M. S., Zhou, J., Peng, Z., Zhang, X., Wang, X., Shen, L., & Li, J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09447-x · Cited by 8
“HER2 amplification as a negative predictor of the response to cetuximab was also proposed in earlier studies [12, 13].”
ResultKim, S., Cha, Y., Lim, Y., Roh, H., Kang, J., Lee, K., Kim, M. J., Park, J. W., Ryoo, S., Kim, H., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34558 · Cited by 8
Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer
Matos, I. G., Élez, E., Capdevila, J., & Tabernero, J. M. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1220535 · Cited by 9
“Furthermore, these mechanisms do not appear to be mutually exclusive [20,90] making blocking this receptor with antibodies such as trastuzumab or pertuzumab along with inhibition of the kinase domain by lapatinib, a promising strategy.”
BackgroundPharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives
Battaglin, F., Puccini, A., Naseem, M., Schirripa, M., Berger, M. D., Tokunaga, R., McSkane, M., Khoukaz, T., Soni, S., Zhang, W., et al. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.04 · Cited by 9
Pisljar, Z., Markelc, B., Brezar, S. K., Božič, T., Serša, G., Cemazar, M., & Jesenko, T. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118107 · Cited by 7
Advances and Applications of Organ-on-a-Chip and Tissue-on-a-Chip Technology
Moore, M., Sriram, S., Ku, J. C., & Li, Y. (2025) · Bioengineering · doi:10.3390/bioengineering13010009 · Cited by 10
“As cancer sensitivity to anti-tumor medication is variable, OoCs may be used to evaluate multi-drug resistance [73].”
Unsupervised Gene Identification in Colorectal Cancer
Barbiero, P., Bertotti, A., Ciravegna, G., Cirrincione, G., Pasero, E. G. A., & Piccolo, E. (2018) · Smart innovation, systems and technologies · doi:10.1007/978-3-319-95095-2_21 · Cited by 7
Self-citationKhattri, A., Nizamuddin, S., Agrawal, N., Kaushik, S., Kochanny, S. E., Ginat, D. T., Lingen, M. W., Blair, E., & Seiwert, T. Y. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00812-5 · Cited by 7
“In colorectal cancer, mutations in several genes, including KRAS , BRAF and potentially mutations in the RTK/PI3K pathway, have been identi fi ed that confer primary resistance to the cetuximab [24], however, these mutations do not typically occur in HNSCC [25].”
Hu, Y., Zhu, T., Nong, S., Sun, Y., Li, Y., Pan, J., Ma, J., & Zhang, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26093941 · Cited by 10
“Activation of bypass signaling (via amplification or mutations of HER2, FGFR1, MET, and PDGFR) or downstream signaling (via mutations of NRAS, BRAF, PIK3CA, or deletion of PTEN) in cancer cells has been shown to contribute to resistance to anti-EGFR antibodies [21].”
Translating Genomic Profiling to Gastrointestinal Cancer Treatment
Harada, K., Kaya, D. M., Shimodaira, Y., Song, S., Baba, H., & Ajani, J. A. (2017) · Future Oncology · doi:10.2217/fon-2016-0422 · Cited by 7
Quidde, J., Denne, L., Kutscheidt, A., Kindler, M., Kirsch, A., Kripp, M., Petersen, V., Schulze, M., Seraphin, J., Tummes, D., et al. (2017) · Oncology Research and Treatment · doi:10.1159/000454774 · Cited by 7
Volpi, C. C., Gualeni, A. V., Pietrantonio, F., Vaccher, E., Carbone, A., & Gloghini, A. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1440210 · Cited by 7
“Activity of MET inhibitors in pretreated MET-driven gastric cancer/non-small cell lung cancer patients EGFR Inconsistent data in several solid tumors Preclinical activity of EGFR-targeted therapies in EGFR-amplified gastric cancer [29] and colorectal cancer [30].”
BackgroundNeural Biclustering in Gene Expression Analysis
Barbiero, P., Ciravegna, G., Piccolo, E., Cirrincione, G., Cirrincione, M., & Bertotti, A. (2017) · International Conference on Computational Science and Computational Intelligence (CSCI) · doi:10.1109/csci.2017.361 · Cited by 8
“Such resource has been widely characterized at the molecular level [5]-[7] and has been leveraged to reliably anticipate clinical findings [8] with major therapeutic implications.”
BackgroundSelf-citationTundidor, Y., Ponce, L. F., Chao, L., Solozabal, J., Hust, M., Dübel, S., & Rojas, G. (2020) · Scientific Reports · doi:10.1038/s41598-019-57279-w · Cited by 7
Reißig, T. M., Ladigan‐Badura, S., Steinberg, A., Maghnouj, A., Li, T., Verdoodt, B., Liffers, S. T., Pohl, M., Wolters, H. H., Teschendorf, C., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13510 · Cited by 8
Sobani, Z. A., Sawant, A. S., Jafri, M., Correa, A. K., & Şahin, İ. H. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i5.340 · Cited by 10
Jing, C., Wang, T., Ma, R., Cao, H., Wang, Z., Liu, S., Chen, D., Zhang, J., Wu, Y. F., Zhang, Y., et al. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23172 · Cited by 8
Zhao, B., Qu, X., Lv, X., Wang, Q., Bian, D., Yang, F., Zhao, X., Ji, Z., Ni, J., Fu, Y., et al. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.572983 · Cited by 7
Ali, M. A., Zahra, O. S., Morsi, M. I., Safwany, M. M. E., & Feky, S. E. E. (2024) · EJNMMI Reports · doi:10.1186/s41824-024-00233-5 · Cited by 7
Avolio, M., Leto, S. M., Sassi, F. P., Lupo, B., Grassi, E., Catalano, I., Zanella, E. R., Vurchio, V., Cottino, F., Tsantoulis, P. K., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0556 · Cited by 9
“No statistical methods were used to predetermine sample sizes; sample sizes were determined according to previous publications (15, 20) and conformed to PDX minimal information standards (107).”
Self-citationCiprofloxacin and Norfloxacin Hybrid Compounds: Potential Anticancer Agents
Peter, S., & Aderibigbe, B. A. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266288319240206052223 · Cited by 6
Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer
Kratz, J. D., Uboha, N. V., Lubner, S. J., Mulkerin, D. L., Clipson, L. J., Yi, Y., Yu, M., Matkowskyj, K. A., LoConte, N. K., & Deming, D. A. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7074 · Cited by 6
Tailoring antiHer2 treatment strategies in breast cancer and beyond
Fedele, P., Sanna, V., Santoro, A. N., Iaia, M. L., & Fancellu, A. (2022) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2022.100892 · Cited by 8
Suppression of tumor growth and metastasis in Shkbp1 knockout mice
Liu, Q., Li, H., Yang, M., Mei, Y., Niu, T., Zhou, Z., Zhang, X., He, X., Wang, L., & Li, J. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00349-x · Cited by 6
Xu, R., Shao, H., Zhu, J., Ju, Q., & Shi, H. M. (2019) · Medicine · doi:10.1097/md.0000000000014135 · Cited by 6
Homeopathy, Fundamentalism, and the Memory of Water
Milgrom, L. R. (2007) · Current Oncology · doi:10.3747/co.2007.161 · Cited by 8
Loss of VOPP1 Contributes to BET Inhibitor Acquired Resistance in Non–Small Cell Lung Cancer Cells
Sun, L., Wu, Q., Huan, X., Tian, C.-Q., Wang, Y.-Q., & Miao, Z. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-1000 · Cited by 6
SHP2 inhibition improves celastrol-induced growth suppression of colorectal cancer
Zhang, L., Hu, X., Meng, Q., Li, Y., Shen, H., Fu, Y., Zhang, F., Chen, J., Zhang, W., Chang, W., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.929087 · Cited by 5
“9 million patients newly diagnosed in 2020 (Bertotti et al., 2015).”
BackgroundFalcinelli, M., Dell’Omo, G., Grassi, E., Mariella, E., Leto, S. M., Scardellato, S., Lorenzato, A., Arena, S., Bertotti, A., Trusolino, L., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05640-3 · Cited by 5
“CRC patient-derived organoids (PDOs) were generated from patients undergoing metastatic CRC surgical resection [17, 18].”
Self-citationGuo, X., Li, H., Meng, X., Zhao, Z., Zhang, R., Wang, L., & Li, J. (2023) · Molecular Immunology · doi:10.1016/j.molimm.2023.06.004 · Cited by 5
Impact of genomic heterogeneity associated with acquired anti-EGFR resistance in colorectal cancers
Chen, G., & Lin, M. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.05.17 · Cited by 5
“G465E), FGFR1, PDGFRA and MAP2K1 genes as potential mechanisms for primary anti-EGFR resistance (10).”
BackgroundNew strategies in esophageal carcinoma: promises and problems
Xiong, Z., He, J., & Chen, X. L. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.11.22 · Cited by 5
Antoniotti, C., Moretto, R., Rossini, D., Masi, G., Falcone, A., & Cremolini, C. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102135 · Cited by 6
Kourié, H. R., Ibnshamsah, F., Zouein, J., Naim, N., Abbasi, S., Allahloubi, N. M. A., Al-Naqqash, M. A., Alolayan, A. A. M., Alshehri, A., Bitar, N., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0282 · Cited by 6
Mauri, G., Patelli, G., Gori, V., Lauricella, C., Mussolin, B., Amatu, A., Bencardino, K. B., Tosi, F., Bonazzina, E. F., Bonoldi, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1030232 · Cited by 5
“However, a contribution to carcinogenesis and resistance to EGFR inhibition has been highlighted in preclinical and translational studies, making MAP2K1 alterations relevant for MTB discussion before treating these patients with anti-EGFR drugs (at least as monotherapy) (6, 11, 17, 18).”
BackgroundSelf-citationAfolabi, H. A., Salleh, M. S. M., Zakaria, Z., Seng, C. E., Nafi, S. N. M., Aziz, A. A. A., Zainon, W. M. N. W., Irekeola, A. A., Wada, Y., Al-Mhanna, S. B., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-01960-2 · Cited by 6
“CRC is a disease commonly diagnosed at a late stage because affected patients usually present for consultation at a later stage of the disease, hence the attribution with high prevalence in late adulthood and elderly age [27].”
Tumor organoid and tumor-on-a-chip equipped next generation precision medicine
Zhao, W., Zhang, Z., Xu, S., Sun, X., Wang, Y., Ye, J., Wang, X., Gu, Z., & Chen, Z. (2025) · Biofabrication · doi:10.1088/1758-5090/ae0bb3 · Cited by 4
“PDTX models maintain the unique characteristics of individual tumors across different patients, facilitating a more precise reproduction of the intra-tumor and inter-tumor heterogeneity in cancer [39– 41].”
Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers
Bignucolo, A., Scarabel, L., Toffoli, G., Cecchin, E., & Mattia, E. D. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2101447 · Cited by 4
Bianchi, A. S., Marsoni, S., & Siena, S. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2982 · Cited by 4
Self-citationten Hoorn, S., Mol, L., Sommeijer, D. W., Nijman, L. E., van den Bosch, T., de Back, T. R., Ylstra, B., van Dijk, E., van Noesel, C. J. M., Reinten, R. J. A., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.11.006 · Cited by 5
Pathologic Evaluation of Therapeutic Biomarkers in Colorectal Adenocarcinoma
Baranov, E., & Nowak, J. A. (2023) · Surgical pathology clinics · doi:10.1016/j.path.2023.05.002 · Cited by 5
Review on EGFR-ERK1/2 signaling cascade: implications on cell proliferation in health and disease
Fetoh, M. E. A., Abdel‐Fattah, M. M., Afify, H., Ramadan, L. A. A., & Mohamed, W. R. (2023) · Egyptian Pharmaceutical Journal · doi:10.4103/epj.epj_52_23 · Cited by 6
Molecular Testing of Colorectal Cancer in the Modern Era
Vakiani, E. (2017) · Surgical pathology clinics · doi:10.1016/j.path.2017.07.013 · Cited by 8
EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer
Birkman, E., Avoranta, T., Ålgars, A., Korkeila, E. A., Lintunen, M., Lahtinen, L., Kuopio, T., Ristamäki, R., Carpén, O., & Sundström, J. T. T. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.07.028 · Cited by 4
“Acquired resistance to anti-EGFR therapies is known to occur in a substantial proportion of patients, and several studies have been conducted to elucidate the mechanisms involved in this process [22-26].”
Macgregor‐Das, A. M., & Goggins, M. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_56 · Cited by 4
Guo, A.-X., Xiao, F., Shao, W., Zhan, Y., Zhang, L., Xiong, J., Gao, Y., & Yin, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s254747 · Cited by 4
Modulating the phosphorylation status of target proteins through bifunctional molecules
He, Q., Wang, Z., Wang, R., Lu, T., Chen, Y., & Lü, S. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104307 · Cited by 4
Liquid Biopsy in Advanced Colorectal Cancer: Clinical Applications of Different Analytes
Delcuratolo, M. D., Modrego-Sánchez, A., Bungaro, M., Antón-Pascual, B., Terán, S., Dipace, V., Novello, S., García‐Carbonero, R., Passiglia, F., & Graválos-Castro, C. (2023) · Journal of Molecular Pathology · doi:10.3390/jmp4030013 · Cited by 5
Zhou, Y., Zhao, X., Lu, N., Cao, P., Leng, W.-B., Zhu, Q., Gou, H., Zhang, J., Li, X., & Qiu, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111887 · Cited by 4
Bianchi, A. S., & Siena, S. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_19 · Cited by 3
“This finding was confirmed in preclinical experiments (Bertotti et al. 2015) as well as clinical cohorts (Personeni et al. 2008; Sartore-Bianchi et al. 2007; Scartozzi et al. 2009), however overt EGFR gene amplification is rarely observed in CRC, and correlation with response has been mainly based…”
BackgroundMethodSelf-citationHou, H., Liu, D., Zhang, C., Jiang, Y., Lu, G., Zhou, N., Yang, X., Zhang, X., Li, Z., Zhu, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21349 · Cited by 3
“To examine the effect of somatic genetic changes in CRC that caused a response to anti-EGFR antibody therapy, a study was conducted to complete exome sequencing and copy number analyses of patient-derived tumor grafts and targeted genomic analyses of tumors, all of which were KRAS wild-type [11].”
MethodXiong, Q., Zeng, Z., Yang, Y., Wang, Y., Xu, Y., Zhou, Y., Liu, J., Zhang, Z., Qiu, M., & Zhu, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.872630 · Cited by 3
Jin, Y., Chen, P., Zhou, H.-J., Mu, G., Wu, S., Zha, Z., Ma, B., Han, C., & Chiu, M. L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1505868 · Cited by 6
“Similarly, EGFR (gene: EGFR ) expression, mutation status, and ampli fi cation were predictive biomarkers for cetuximab in both clinical and preclinical settings (20, 34, 35).”
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
Vera, R., Salgado, M., Safont, M. J., Gallego-Plazas, J., González‐Flores, E., Élez, E., & Aranda, E. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02475-8 · Cited by 4
Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer
Miyamoto, Y., Zhang, W., & Lenz, H. (2016) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-016-0543-z · Cited by 3
Current Utility and Future Applications of ctDNA in Colorectal Cancer
Day, D., Frentzas, S., Naidu, C. A., Segelov, E., & Green, M. M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82316 · Cited by 3
“There is a battery of pre-clinical and clinical evidence which points to the acquisition of molecular mechanisms of resistance associated with aberrations in the RAS-MEK-mitogen-activated protein kinases (MAPK), pathway [2, 42, 81, 82].”
BackgroundUnmasking circulating tumor cells
Swennenhuis, J. F. (2016) · doi:10.3990/1.9789036542685 · Cited by 3
Han, H., Li, Y., Qin, W., Wang, L., Yin, H., Su, B., & Yuan, X. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.21.423755 · Cited by 4
Patient-Derived-Xenografts in Mice: A Preclinical Platform for Cancer Research
Cocco, E., & de Stanchina, E. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041381 · Cited by 5
Freeman, T. J., George, T. J., Jacobs, S. A., Yothers, G., Kolevska, T., Feng, H., Lipchik, C., Maley, S. K., Song, N., Srinivasan, A., et al. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04802-8 · Cited by 5
“Bertotti et al. [22] studied the response to C in quadruple-wt mCRC xenopatients.”
Hallberg, D. L., Eastman, A. C., Koul, S., Bruhm, D. C., Papp, E., Davenport, S., Adleff, V., Ferreira, L., Niknafs, N., Medina, J. E., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0147 · Cited by 2
“Fragmented genomic DNA from tumor and normal samples were used for Illumina TruSeq library construction (Illumina) according to the manufacturer’s instructions or as previously described (32).”
Self-citationNovel bispecific T-cell engagers overcoming acquired EGFR resistance
Kühl, L., Löffler, A.-K., Seifert, O., Michler, D., Kuhlmann, M., Russo, G., Kuhn, P., Nowack, H., Frenzel, A., Schirrmann, T., et al. (2026) · mAbs · doi:10.1080/19420862.2026.2674236 · Cited by 2
DNA Microarray Classification: Evolutionary Optimization of Neural Network Hyper-parameters
Barbiero, P., Bertotti, A., Ciravegna, G., Cirrincione, G., & Piccolo, E. (2019) · Smart innovation, systems and technologies · doi:10.1007/978-981-13-8950-4_28 · Cited by 2
Self-citationLi, W., Chen, W., Wang, J., Zhao, G., Chen, L., Wan, Y., Luo, Q., Li, W., Huang, H., Li, W., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12518 · Cited by 2
Tang, L., Zhu, Y., Du, Y., Long, X., Long, Y., Tang, Y., & Liu, J. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05783-6 · Cited by 2
“In addition, IRS2 amplification, firstly confirmed in a study of PI3K signaling pathway changes in colorectal cancer (Parsons et al. 2005), has been a vital indicator of sensitivity to targeted therapy in colorectal and lung cancers (Bertotti et al. 2015).”
BackgroundResistance of Colorectal Tumors to Anti-EGFR Antibodies
Trusolino, L., & Leto, S. M. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_1 · Cited by 2
Self-citationUnderstanding Cancer Phenomenon at Gene Expression Level by using a Shallow Neural Network Chain
Barbiero, P., Bertotti, A., Ciravegna, G., Cirrincione, G., Piccolo, E., & Tonda, A. P. (2019) · Smart innovation, systems and technologies · doi:10.1007/978-981-13-8950-4_26 · Cited by 2
Self-citationERBB2 in anti-EGFR-resistant colorectal cancer: cancer stem cells come into play
Mouillet‐Richard, S. (2021) · Gut · doi:10.1136/gutjnl-2020-323924 · Cited by 2
Supervised Gene Identification in Colorectal Cancer
Barbiero, P., Bertotti, A., Ciravegna, G., Cirrincione, G., Pasero, E. G. A., & Piccolo, E. (2018) · Smart innovation, systems and technologies · doi:10.1007/978-3-319-95095-2_23 · Cited by 3
Self-citationMolecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Ma, Z., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00007-9 · Cited by 2
Bianchi, A. S., Marsoni, S., Amatu, A., Torri, V., Bonoldi, E., Bardelli, A., Trusolino, L., & Siena, S. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00805 · Cited by 2
Self-citationRiera, P., Rodríguez‐Santiago, B., Lasa, A., González‐Quereda, L., Martín, B., Salazar, J., Sebio, A., Manrique, A. C. V., Minguillón, J., Camps, C., et al. (2020) · Cancers · doi:10.3390/cancers12082245 · Cited by 2
“described novel missense mutations located in/near the catalytic domain as mechanisms of anti-EGFR resistance [23].”
BackgroundResultMolecular Diagnostics and Genomic Profiling in Individualized Therapies of Gastrointestinal Cancers
Kamgar, M., & Korn, W. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-18890-0_34 · Cited by 1
Chang, S. H., Ice, R. J., Chen, M. M., Sidorov, M. K., Woo, R. W. L., Rodriguez-Brotons, A., Jian, D., Kim, H. K., Kim, A., Stone, D. E., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0486 · Cited by 1
Ueda, S., Tanaka, T., Hirosuna, K., Miyamoto, S., Murakami, H., Nishie, R., Tsuchihashi, H., Toji, A., Morita, N., Hashida, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031486 · Cited by 2
Emmett, M. J., Quintanilha, J. C. F., Graf, R. P., Li, G., Tukachinsky, H., Schrock, A. B., Morley, S., Fisher, V. A., Oxnard, G. R., Lieu, C. H., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100036 · Cited by 2
“…EGFR , PDGFRA mutations or rearrangements; NTRK1 , NTRK2 , NTRK3 fusions; and ALK , RET , ROS1 rearrangements) 18,28,40,42,43,50 ; sensitivity alterations including (v) EGFR a mpli fi cation 41 ; and (vi) FLT3 ampli fi cation 18 was evaluated as a separated group due to con fl icting data.”
Kschonsak, Y. T., Liang, W., Chan, J., Kan, D., Nguyen, T. T. T., Ruiz, K., Kee, Y.-S., Tsai, W. K., Xi, H., Москаленко, М., et al. (2026) · Science Advances · doi:10.1126/sciadv.adx3959 · Cited by 2
“S6D) ( 31 ).”
Ma, Z., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00021-3 · Cited by 1
Sato, M., Yamamoto, Y., Moriwaki, T., Fukuda, K., & Tsuchiya, K. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102073 · Cited by 1
Ro, H., Ishiyama, S., Sugimoto, K., & SAKAMOTO, K. (2025) · Juntendō Igaku/Juntendo igaku · doi:10.14789/ejmj.jmj25-0012-r · Cited by 2
Harmych, S. J., Joshi, N., Tanaka, H., Bogatcheva, G. T., Ramirez, M. A., Graves‐Deal, R., Tydings, C. W., Elia, M. T., Mueller, H. R. L., Silvestri, I. M., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218607 · Cited by 1
Leto, S. M., Sassi, F. P., Zanella, E. R., Vurchio, V., Cottino, F., Ferri, M., Damico, A., Grassi, E., Bertotti, A., & Trusolino, L. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08900-0 · Cited by 1
“The size of the animal groups was calculated to measure a 50% difference between placebo and treatment groups with a power of 80% and a P value of 0.05; sample sizes were similar to those reported in previous publications [28, 54] and conformed to PDX minimal information standards [55].”
InfluentialSelf-citationRunning a PDX Core Laboratory or a PDX Support Program
Krivtsov, A. V., Mattar, M. S., Uthamanthil, R., & de Stanchina, E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804010-2.00012-6 · Cited by 1
Søreide, K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00019-3 · Cited by 1
Molecular Determinants of Gastrointestinal Cancers
Battaglin, F., Randon, G., Raimondi, A., Pagani, F., Arai, H., Pietrantonio, F., & Lenz, H. (2021) · Advances in Oncology · doi:10.1016/j.yao.2021.02.026 · Cited by 1
Metadata
- Authors
- Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., Niknafs, N., Nesselbush, M., Lytle, K., Sassi, F., Cottino, F., Migliardi, G., Zanella, E. R., Ribero, D., Russolillo, N., Mellano, A., Muratore, A., Paraluppi, G., Salizzoni, M., Marsoni, S., Kragh, M., Lantto, J., Cassingena, A., Li, Q. K., Karchin, R., Scharpf, R., Sartore-Bianchi, A., Siena, S., Diaz, L. A., Trusolino, L., & Velculescu, V. E.
- Affiliations
- Istituto Nazionale Biostrutture e Biosistemi (IT)
- Johns Hopkins University (US)
- Candiolo Cancer Institute (IT)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- Symphogen (Denmark) (DK)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- University of Milan (IT)
- Corresponding author
- Bertotti, Andrea
- Trusolino, Livio
- Velculescu, Victor E.
- ORCID
- Bertotti, Andrea
- Papp, Eniko
- Jones, Siân
- Adleff, Vilmos
- Anagnostou, Valsamo
- Lupo, Barbara
- Sausen, Mark
- Phallen, Jillian
- Hruban, Carolyn A.
- Tokheim, Collin
- Niknafs, Noushin
- Nesselbush, Monica
- Sassi, Francesco
- Cottino, Francesca
- Migliardi, Giorgia
- Zanella, Eugenia R.
- Ribero, Dario
- Russolillo, Nadia
- Mellano, Alfredo
- Muratore, Andrea
- Salizzoni, Mauro
- Marsoni, Silvia
- Kragh, Michael
- Lantto, Johan
- Cassingena, Andrea
- Li, Qing Kay
- Karchin, Rachel
- Scharpf, Robert
- Siena, Salvatore
- Diaz, Luis A.
- Trusolino, Livio
- Velculescu, Victor E.
- Venue
- Nature
- Published
- 2015-09-30
- Volume
- 526
- Issue
- 7572
- Pages
- 263-267
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4878148
- OpenAlex
- W2102354469
- Cited by
- 479
- References
- 41
- Citations by year
- 2026: 16 · 2025: 28 · 2024: 37 · 2023: 35 · 2022: 47 · 2021: 50 · 2020: 47 · 2019: 59 · 2018: 56 · 2017: 57 · 2016: 43 · 2015: 3
- FWCI
- 23.15
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-02-16)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (5r01ca121113-15)
- National Cancer Institute (R01-CA121113, CA-121113, P30CA006973)
- National Institute of General Medical Sciences (T32GM007057)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- EGFR inhibition, anti-EGFR antibody therapy, cetuximab, panitumumab, treatment resistance, primary resistance, somatic mutations, ERBB2, FGFR1, PDGFRA, MEK1, KRAS wild-type
- MeSH terms
- Cetuximab, Panitumumab, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Mutation, Colorectal Neoplasms, Genome, Human, Proto-Oncogene Proteins p21(ras), Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Receptor, Platelet-Derived Growth Factor alpha, Xenograft Model Antitumor Assays, Genomics, MAP Kinase Kinase 1, Mice, Receptor, Fibroblast Growth Factor, Type 1, Insulin Receptor Substrate Proteins, DNA Copy Number Variations, Molecular Targeted Therapy, Exome, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.